TriSalus Life SciencesTLSI +3.80%29 Days Payable is 268.33 as of Mar. 2026, which is 33% below its 10-year median of 397.74. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 793 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 81.08% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TriSalus Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TriSalus Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Days Payable of 268.33 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TriSalus Life Sciences and its competitors. This is 33% below median its historical median of 397.74. Over the past decade, TriSalus Life Sciences' Days Payable has ranged from 138.24 to 584.14. According to the industry distribution chart, TriSalus Life Sciences ranks #150 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is TriSalus Life Sciences' Days Payable too high?
TriSalus Life Sciences' current Days Payable of 268.33 is 33% below median its 10-year median of 397.74. Over the past 10 years, this metric has ranged from a low of 138.24 to a high of 584.14. The Medical Devices & Instruments industry median Days Payable is 67.87. TriSalus Life Sciences' value of 268.33 is 295.4% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #150 out of 793 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Days Payable compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #150 out of 793 companies for Days Payable. This places TriSalus Life Sciences in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. TriSalus Life Sciences' value of 268.33 is 295.4% above this benchmark. Historically, TriSalus Life Sciences' own Days Payable has ranged from 138.24 to 584.14 over the past decade. While the company's 10-year median is 397.74 vs. the industry median of 67.87, TriSalus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Days Payable of 268.33 is 295.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Days Payable is 268.33, which is 33% below median its own 10-year median of 397.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Days Payable is 268.33, which is 33% below median its 10-year median of 397.74 and 295.4% above the Medical Devices & Instruments industry median of 67.87. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Days Payable is 268.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31.
GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.
Key valuation signals for TLSI:
Days Payable: 268.33 (33% below median its 10-year median of 397.74)
GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
Industry Position: 295.4% above the Medical Devices & Instruments median (#150 of 793)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
